Geoffrey Ira Shapiro
Brigham and Women's Hospital · 2,082 works · 57,998 citations · h-index 115
Top works
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
- Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
- LKB1 modulates lung cancer differentiation and metastasis
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
- A novel p16INK4A transcript.
- Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
- Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
- Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
- Targeting CDK4 and CDK6: From Discovery to Therapy
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers